Recent news on Pegaptanib Sodium

Study Fails to Demonstrate Differences between Intravitreal ...  -  May 14, 2007
DG News...treated with verteporfin photodynamic therapy (PDT) together with either intravitreal injections of either Macugen (pegaptanib sodium) or triamcinolone.

VEGF inhibitors face regulatory, availability problems in France  -  May 17, 2007
OSN SuperSite (subscription),Macugen (pegaptanib sodium, OSI/Pfizer) was authorized for sale in France in January 2006, but Lucentis (ranibizumab, Genentech) can only be licensed for

Study finds little further benefit from Avastin after prior ...  -  May 10, 2007
OSN SuperSite (subscription),Avastin (bevacizumab, Genentech) as either their primary treatment or as "rescue" therapy after treatment with Macugen (pegaptanib sodium, OSI/Pfizer).

OSI Pharmaceuticals Announces First Quarter 2007 Financial Results  -  Apr 27, 2007
PharmaLive.com (press release),Our eye disease business consists principally of Macugen(R) (pegaptanib sodium injection), our marketed product for the treatment of wet AMD,

Pfizer spies pSivida's injectable eye treatment  -  Apr 4, 2007
DrugResearcher.com,Xalatan (latanoprost) for open-angle glaucoma or ocular hypertension, and Macugen (pegaptanib sodium) for age-related macular degeneration (AMD).

Trials That Matter: Two Faces of Progress in the Treatment of Age ...  -  Apr 2, 2007
Annals of Internal Medicine...treatment of patients with wet macular degeneration have been photodynamic therapy with verteporfin and intravitreous injections of pegaptanib sodium.

Cost of line of vision in AMD supports need for solutions, surgeon ...  -  Feb 28, 2007
OSN SuperSite (subscription),...$448 for photodynamic therapy, $1248 for Macugen (pegaptanib sodium, OSI/Pfizer) and $687 for Lucentis (ranibizumab, Genentech).

OSI Pharmaceuticals Announces Year End 2006 Financial Results  -  Feb 23, 2007
Oxfordshire Bioscience Network (press release),...and the addition of Macugen(R) (pegaptanib sodium injection)-related revenue streams. Total worldwide net sales of Tarceva for 2006 were $650 million,

OSI Pharmaceuticals Announces Year End 2006 Financial Results  -  Feb 21, 2007
Business Wire (press release),The increase was primarily due to the growth in revenues arising from worldwide Tarceva® (erlotinib) sales, and the addition of Macugen® (pegaptanib sodium

New cancer target could be as important as VEGF  -  Jan 31, 2007
DrugResearcher.com,EyeTech Pharmaceuticals, in conjunction with Pfizer, markets the anti-VEGF drug Macugen (pegaptanib sodium injection) as a treatment for all types of wet

OSI Pharmaceuticals Announces Third Quarter 2006 Financial Results  Nov 6, 2006
...due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales, and the addition of Macugen(R) (pegaptanib sodium injection)-related revenue ... -Genetic Engineering News (press release), OSI Pharmaceuticals Announces Third Quarter 2006 Financial Results  Nov 6, 2006
...primarily due to the growth in revenues arising from worldwide Tarceva® (erlotinib) sales, and the addition of Macugen® (pegaptanib sodium injection)-related ... -Business Wire (press release), EyeGate Pharma Starts US Operations in Waltham, MA  Nov 3, 2006
...in Lexington, MA (now OSI), where he built a world-class lab to support the development of the marketed product, Macugen® (pegaptanib sodium injection) for age ... -dBusinessNews Boston (press release), OSI Pharmaceuticals to Announce Third Quarter 2006 Financial ...  Oct 26, 2006
Macugen ® (pegaptanib sodium injection) is approved in the United States and Europe for the treatment of neovascular age-related macular degeneration. ... -Business Wire (press release), National Institutes of Health Stimulates the Development and ...  Oct 11, 2006
At this point, two anti-VEGF therapies, Macugen® (pegaptanib sodium) and LucentisTM, have already been approved by FDA specifically for the treatment of ... -PipelineReview.com (press release), Wet Age-Related Macular Degeneration Causes Significant Health ...  24 Sep 2006
Elsewhere at the meeting, investigators presented several reports on the use of pegaptanib sodium injection (Macugen®), which is the first therapy to target ... -Medical News Today

Intravitreal Pegaptanib Shows Promise As Diabetic Retinopathy ...  Sep 18, 2006
CANNES, FRANCE -- September 18, 2006 -- Blockade of selective vascular endothelial growth factor (VEGF) with pegaptanib sodium injection (Macugen(R)) postpones ... -DG News

OSI Pharmaceuticals Launches Study of Tarceva as Adjuvant ...  Sep 21, 2006
Macugen(R) (pegaptanib sodium injection) is approved in the United States and Europe for the treatment of neovascular age-related macular degeneration. ... -PharmaLive.com

Delivery Improvements Of The AMD-drug Lucentis On The Way  Sep 20, 2006
RNA-based anti-VEGF therapies pegaptanib sodium and bevasiranib appear to be inferior to Lucentis because pegaptanib does not improve visual acuity and ... -Medical News Today

The eyes have it  -  Nov 26, 2006
Toronto Sun,Another is a pegaptanib sodium injection called Macugen which works by blocking a protein that promotes blood vessel growth. Still in clinical trials is

The Crowded Field of VEGF and VEGF-R Targeting Drugs  Aug 16, 2006
Pegaptanib sodium has been the first approved anti-VEGF drug for treatment of wet age-related macular degeneration (AMD), closely followed by the antibody ... -PipelineReview.com

OSI Pharmaceuticals Announces Second Quarter 2006 Financial ...  Aug 7, 2006
...due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales, and the addition of Macugen(R) (pegaptanib sodium injection)-related revenue ... -Genetic Engineering News

OSI Pharmaceuticals Announces Second Quarter 2006 Financial ...  Aug 7, 2006
...in theUnited States and with Roche throughout the rest of the world.Macugen(R) (pegaptanib sodium injection) is approved in the UnitedStates and Europe for the ... -Finanzen.net

OSI Pharmaceuticals Announces That Roche Has Received Negative ...  Jul 28, 2006
Macugen(R) (pegaptanib sodium injection) is approved in theUnited States and Europe for the treatment of neovascular age-relatedmacular degeneration. ... -Finanzen.net

OSI Pharmaceuticals Announces That Roche Has Received Negative ...  Jul 28, 2006
Macugen(R) (pegaptanib sodium injection) is approved in the United States and Europe for the treatment of neovascular age-related macular degeneration. ... -Genetic Engineering News

OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen ...  Jun 26, 2006
...acuity with sEquential treatment of neovascuLar AMD), a Phase IV trial that will explore the safety and efficacy of Macugen(R) (pegaptanib sodium injection) as ... -PharmaLive.com

OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R) ...  Jun 26, 2006
...acuity with sEquential treatment ofneovascuLar AMD), a Phase IV trial that will explore the safety andefficacy of Macugen(R) (pegaptanib sodium injection) as a ... -Finanzen.net

OSI/Pfizer Response to New Therapies for Neovascular Age-related ...  Jun 30, 2006
Nearly 70,000 patients have already been treated with Macugen ® (pegaptanib sodium injection), which offers proven efficacy and safety for up to two years ... -PharmaLive.com

Lux Biosciences Appoints to Board of Directors David Guyer, SVLS ...  Jul 11, 2006
The company developed and gained regulatory approval for Macugen(TM) (pegaptanib sodium injection), the first approved VEGF-inhibitor to treat macular ... -PharmaLive.com



Pegaptanib Sodium Leads to Significant Increase in Intraocular ...  May 1, 2006
FT. LAUDERDALE, FL -- May 1, 2006 -- Patients whose age-related macular degeneration (ARMD) is treated with pegaptanib sodium (Macugen) may run the risk of ... - DG News

OSI Pharmaceuticals Summarizes Macugen (pegaptanib sodium ...  May 4, 2006
...(NASDAQ: OSIP) today provided an informational update summarizing highlights from presentations made regarding Macugen(R) (pegaptanib sodium injection) at this ... - PharmaLive.com

OSI Pharmaceuticals to Present at the Bank of America Health Care ...  May 9, 2006
Macugen(R) (pegaptanib sodium injection) is approved in the United States and Europe for the treatment of neovascular age-related macular degeneration. ... - Genetic Engineering News

OSI Pharmaceuticals Announces First Quarter 2006 Financial Results  May 8, 2006
...increase is primarily due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales, and Macugen(R) (pegaptanib sodium injection)-related ... - Genetic Engineering News

Triple Regimen Safe and Effective for Choroidal Neovascularization ...  May 2, 2006
...who receive triple therapy with a combination of intravitreal triamcinolone, photodynamic therapy (PDT) and intravitreal Macugen (pegaptanib sodium) to treat ... - DG News

OSI Pharmaceuticals Announces Management Changes to Its Eye ...  May 1, 2006
...of the Company's eye disease franchise which includes its neovascular age-related macular degeneration product, Macugen(R) (pegaptanib sodium injection). ... - PharmaLive.com





FDA MedWatch - Macugen (pegaptanib sodium injection) Labeling ...  Apr 7, 2006
Pharmaceuticals notified healthcare professionals of important changes in the approved product labeling for Macugen (pegaptanib sodium injection), including ... - PharmaLive.com

OSI Pharmaceuticals IGF-1R Inhibitor Program Featured in 97th ...  Apr 5, 2006
Macugen(R) (pegaptanib sodium injection) is approved in the United States and Europe for the treatment of neovascular age-related macular degeneration. ... - PharmaLive.com

MACUGEN(TM) represents a substantial improvement in the treatment ...  Mar 16, 2006
...announced today that MACUGEN(TM) (pegaptanib sodium injection) has now been recognized by the Human Drug Advisory Panel (HDAP) New Medicine Review as providing ... - Canada NewsWire

OSI Pharmaceuticals Announces Year End 2005 Financial Results  Mar 8, 2006
2005 were $309 million. Total US sales of Macugen(R) (pegaptanib sodium injection) for 2005 were $185 million. Total revenues for ... - Oxfordshire Bioscience Network



OSI Pharmaceuticals Announces European Regulatory Approval for ...  Feb 2, 2006
...that the European Commission has granted its development and marketing partner, Pfizer Inc, approval to market Macugen(R) (pegaptanib sodium injection) for the ... - DG News

International Approvals: Tamiflu, Macugen, Naglazyme  Feb 13, 2006
...phosphate capsules and suspension, allowing their use for the prophylaxis of influenza in children aged 1 through 12 years; pegaptanib sodium injection for the ... - Medscape (subscription)

Intensifying research to fight diseases  Feb 3, 2006
Lyrica) for neuropathic pain and as an adjunctive therapy for partial epileptic seizures, indiplon for insomnia, pegaptanib sodium injection (Macugen) for age ... - INQ7.net,

European Commission Approves Macugen for Treatment of All Types of ...  Feb 2, 2006
FirstCall/ -- Pfizer Inc said today that the European Commission has granted marketing authorization for Macugen(R) (pegaptanib sodium injection) for the ... - PR Newswire,

OSI Pharmaceuticals Announces European Regulatory Approval for ...  Feb 2, 2006
...that the European Commission has granted its development and marketing partner, Pfizer Inc, approval to market Macugen(R) (pegaptanib sodium injection) for the ... - DG News

Association of PrMACUGEN* (pegaptanib sodium injection) with ...  Jan 23, 2006
Health Canada Endorsed Important Safety Information on PrMACUGEN(*) (pegaptanib sodium injection) KIRKLAND, QC, Jan. 23 /CNW Telbec ... - Canada NewsWire

OSI Pharmaceuticals Announces Two Corporate Governance Changes  Feb 6, 2006
Macugen(R) (pegaptanib sodium injection) is approved in the United States for the treatment of neovascular age-related macular degeneration. ... - Genetic Engineering News

Intensifying research to fight diseases  Feb 3, 2006
Lyrica) for neuropathic pain and as an adjunctive therapy for partial epileptic seizures, indiplon for insomnia, pegaptanib sodium injection (Macugen) for age ... - INQ7.net

European Commission Approves Macugen for Treatment of All Types of ...  Feb 2, 2006
FirstCall/ -- Pfizer Inc said today that the European Commission has granted marketing authorization for Macugen(R) (pegaptanib sodium injection) for the ... - PR Newswire

Pfizer's Macugen cleared for marketing in EU  Feb 3, 2006
Macugen (pegaptanib sodium injection) has been proven to prevent and reduce vision loss in patients with neovascular AMD, and becomes the first treatment to be ... - Pharma Times (subscription)

PR Pharmaceuticals (PRP) Announces Collaboration With OSI ...  Jan 11, 2006
...agreement with OSI Pharmaceuticals to collaborate on the development of a sustained release formulation of Macugen(R) (pegaptanib sodium injection), a novel ... - PR Newswire

OSI Pharmaceuticals Announces Net US Tarceva(R) Sales for Fourth ...  Jan 11, 2006
January 9, 2006 the Company provided updated guidance of net product revenue of $183 million to $185 million for Macugen(R) (pegaptanib sodium injection) for ... - Business Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional